Meeting
2015 ASCO Annual Meeting
Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer.
Authors
Bassel F. El-Rayes
Winship Cancer Institute of Emory University, Atlanta, GA
Bassel F. El-Rayes , Charles A. Staley , Roberto Diaz , Patrick S. Sullivan , Walid Labib Shaib , Jerome Carl Landry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
01554969
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3596)
DOI
10.1200/jco.2015.33.15_suppl.3596
Abstract #
3596
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
First Author: Brian G. Czito
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
First Author: Ewa Mrozek